Evoke Pharma Celebrates New Patent for GIMOTI
Evoke Pharma, Inc. (NASDAQ: EVOK), a leader in specialty pharmaceuticals, is thrilled to share exciting news regarding its innovative treatment, GIMOTI®. The company has officially received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a crucial U.S. patent application focused on GIMOTI, a nasal spray formulation designed specifically for patients suffering from gastroparesis.
Impact of the New Patent on GIMOTI's Market Presence
This new patent builds on the foundation laid by U.S. Patent No. 11,517,545 and promises to extend protections of GIMOTI well into December 2036. This step not only reaffirms Evoke's commitment to enhancing its intellectual property portfolio but also reinforces GIMOTI’s market exclusivity in a competitive landscape.
CEO's Insights on GIMOTI's Enhancement
Matt D’Onofrio, the CEO of Evoke Pharma, expressed optimism about this milestone, stating, "This new patent allowance adds meaningful value to the GIMOTI franchise by reinforcing protection around how and in whom the therapy is utilized.” He emphasizes that GIMOTI is particularly valuable for patients with diabetic gastroparesis, a condition where oral medications can be less effective due to delayed gastric emptying.
Advocating for Gastroparesis Awareness
In a demonstration of their commitment to the gastroparesis community, Evoke Pharma is taking proactive steps to support Gastroparesis Awareness Month. This initiative is vital as it encourages greater understanding of treatment options and increases awareness for those impacted by this chronic condition.
Overview of GIMOTI's Unique Features
What sets GIMOTI apart is that it is the only FDA-approved nasal spray formulation of metoclopramide available for adults, effectively addressing symptoms related to diabetic gastroparesis. This non-oral delivery method is particularly crucial for patients, as it allows for more predictable medication absorption under challenging circumstances such as vomiting, a common symptom of gastroparesis.
The Path Ahead for Evoke Pharma
Looking to the future, Evoke Pharma is not resting on its laurels. The company has already filed additional U.S. continuation applications to pursue more claims relevant to treatments tailored for this specific patient demographic. This strategic move underscores Evoke Pharma’s proactive approach to fostering innovation in its offerings.
Understanding Diabetic Gastroparesis
Diabetic gastroparesis is a condition that affects millions across the globe. It leads to delayed gastric emptying, causing a host of gastrointestinal and systemic complications. The need for effective treatments like GIMOTI becomes crucial, as they can significantly improve patients' quality of life.
Commitment to Safety and Efficacy
Evoke Pharma is deeply committed to patient safety. GIMOTI comes with significant safety information, including warnings about potential serious side effects such as tardive dyskinesia. Patients are advised to carefully monitor their use of metoclopramide and consult healthcare providers for guidance on long-term treatment options.
Frequently Asked Questions
What is GIMOTI used for?
GIMOTI is used to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.
How does the new patent affect GIMOTI?
The new patent allows Evoke Pharma to maintain market exclusivity for GIMOTI, extending the protection until December 2036.
Why is GIMOTI significant for diabetic patients?
GIMOTI is significant as it provides a non-oral treatment option for patients who face challenges with traditional oral medications due to delayed gastric emptying.
How can patients stay informed about gastroparesis?
Patients can stay informed by participating in initiatives like Gastroparesis Awareness Month and following updates from Evoke Pharma.
Where can I find more information about Evoke Pharma?
For comprehensive details about Evoke Pharma and its products, visit their official website.
